Kava (Piper methysticum G. Forst) for Substance Use Disorders: A Review of Mechanism, Pharmacology, Clinical Evidence, and Therapeutic Potential
Open Access
Abstract
Substance use disorders (SUDs) remain a major public health concern and contribute substantially to compromised quality of life, mortality, and healthcare burden. In the United States alone, millions of individuals are affected by alcohol use disorder (AUD), tobacco use disorder (TUD), and opioid use disorder (OUD), with many cases complicated by co-existing anxiety and stress-related disorders. Piper methysticum G. Forst (kava), a traditional South Pacific plant preparation, has gained attention for its anxiolytic, sedative, and sleep-promoting properties. Its pharmacological effects are primarily attributed to a set of lipophilic compounds known as kavalactones, which have been reported to modulate GABAA receptor activity, dopaminergic and adrenergic signaling pathways, monoamine oxidase-B activity, cannabinoid receptor type 1 activity, and voltage-gated ion channels. Peer-reviewed literature was identified through searches of PubMed, NIH resources, and other scientific databases using terms related to kava, kavalactones, addiction, anxiety, stress, insomnia, and SUDs. Both clinical and preclinical studies were reviewed, including investigations of neurotransmitter systems and addiction-related signaling pathways. The current literature suggests that the strongest rationale for kava use exists in AUD, where anxiety and stress are established contributors to relapse. Evidence supporting kava use in TUD and OUD is largely theoretical, while concerns regarding hepatotoxicity, cytochrome P450 interactions, product variability, and additive risk remain important barriers to its clinical application. In summary, current evidence does not support kava as a replacement for established therapies, while its unique pharmacological profile warrants further investigation as a potential adjunctive treatment for withdrawal and relapse in SUDs.Keywords
This publication has 88 references indexed in Scilit:
- Effect of kava (Piper methysticum) on peripheral gene expression among individuals with generalized anxiety disorder: A post hoc analysis of a randomized controlled trialPhytotherapy Research, 2023
- Alcohol-Related Deaths During the COVID-19 PandemicJAMA, 2022
- Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependenceCochrane Database of Systematic Reviews, 2014
- Pharmacological Treatments for Smoking CessationJAMA, 2014
- Kavalactone Metabolism in Rat Liver MicrosomesPhytotherapy Research, 2011
- Risk of Kava Hepatotoxicity and the FDA Consumer AdvisoryJAMA, 2010
- Anxiolytic properties of Piper methysticum extract samples and fractions in the chick social–separation–stress procedurePhytotherapy Research, 2003
- Kava extract versus placebo for treating anxietyCochrane Database of Systematic Reviews, 2003
- Kavapyrone enriched extract fromPiper methysticum as modulator of the GABA binding site in different regions of rat brainPsychopharmacology, 1994
- Uptake into Mouse Brain of Four Compounds Present in the Psychoactive Beverage KavaJournal of Pharmaceutical Sciences, 1988